GlobeNewswire by notified

Information on the financial conditions of the termination of Édouard Guinotte as Chairman and Chief executive officer of Vallourec – other governance-related matters

Share






Information on the financial conditions of the termination of Édouard Guinotte as Chairman and Chief executive officer of Vallourec – other governance-related matters

(Disclosed in accordance with the recommendations of the Afep-Medef corporate governance code)

Meudon (France), March 28th, 2022 – In accordance with the recommendations of the Afep-Medef corporate governance code, Vallourec is publishing information on the financial conditions in relation to the cessation of the duties of Mr. Édouard Guinotte as Chairman and Chief executive officer of Vallourec, as approved by the Board of Directors on March 26th, 2022 upon the recommendations of the Remuneration Committee which took place on the same day.

Mr. Édouard Guinotte’s severance package will be put forward for approval during the upcoming Annual General Meeting of the shareholders.

1. Fixed annual compensation for the fiscal year 2022

The Board of Directors acknowledged that the fixed compensation of Mr. Édouard Guinotte for the fiscal year 2022 will be EUR 130,434.78 gross. It was calculated proratatemporis from January 1st, 2022 until the cessation of his duties as Chairman and Chief executive officer.

2. Variable annual compensation

For the fiscal year 2021, the Board of Directors set the achievement rate for the targets at 98.93%. The variable annual compensation of Mr. Édouard Guinotte will therefore be EUR 593,580 gross.

For the period from January 1st, 2022 to March 20th, 2022, the Board of Directors decided to calculate proratatemporis Mr. Édouard Guinotte’s variable remuneration on the basis of an achievement of 100% of the targets, corresponding to an amount of EUR 130,434.78.

In accordance with the applicable legal provisions, the payment of this variable compensation will be subject to the approval of the upcoming Annual General Meeting of the shareholders.

3. Unvested long-term incentive compensation

It is reminded that the Board of Directors and the general meeting of the shareholders approved respectively on July 27th, 2021 and on September 7th, 2021 the setting up of a plan for the allocation of (i) ordinary shares and (ii) preferred shares convertible into ordinary shares, all subject to attendance and/or performance conditions, as the case may be, with a 33.33% : 66.67% ratio, for the benefit of the Chairman and Chief executive officer, the Deputy chief executive officer, the members of the Executive Committee and certain executives.

On October 13th, 2021, Mr. Édouard Guinotte was thus granted a total of 1,002,767 free shares under the plan, consisting in (i) 292,852 Tranche 1 free shares, (ii) 292,852 Tranche 2 free shares, (iii) 292,852 Tranche 3 free shares and (iv) 124,211 Tranche 4 free shares.

Pursuant to the plan and the terms and conditions of the free shares, all of Mr. Édouard Guinotte’s T2 free shares, T3 free shares and T4 free shares, and 80% of his T1 free shares shall lapse. Mr. Édouard Guinotte shall only be entitled to 20% of the 292,852 Tranche 1 free shares.

In relation to the rights of Mr. Édouard Guinotte under other employee equity plans, the provisions of such plans will be strictly enforced by the Company.

4. Severance indemnity and non-compete indemnity

The Board of Directors authorized the Company and Vallourec Oil and Gas France to conclude with Mr. Édouard Guinotte a settlement agreement (the "Agreement") in the context of the cessation of his duties as Chairman and Chief executive officer. The Agreement provides for the payment to Mr. Édouard Guinotte of a settlement indemnity and the activation of the non-competition obligation provided for at the time of the appointment of Mr. Édouard Guinotte. The conclusion of the Agreement was necessary for Vallourec in order to preserve its interests in the context of the departure of his former executive corporate officer, whose employment contract as employee was suspended, by providing for a waiver of any recourse or claim by the latter on the execution and/or the cessation of all its duties within the Vallourec group and by confirming the implementation of a non-compete commitment for a period of 18 months. The conclusion of this Agreement is in line with the objectives of the Afep-Medef corporate governance code.

The commitments made by Vallourec under the Agreement will be subject to the approval of the upcoming Annual General Meeting of the shareholders.

4.1 Settlement indemnity

It is agreed under the Agreement to pay a settlement indemnity in the amount of EUR 883,237.84 gross for the purpose of settling amicably and definitively the terms of the cessation of all the duties of Mr. Édouard Guinotte within the Vallourec group. The payment of this settlement indemnity will be subject to the approval of the upcoming Annual General Meeting of the shareholders.

4.2 Severance pay as employee

It has also been agreed that the employment contract of Mr. Édouard Guinotte, who joined the Group in 1995, which had been entered into with Vallourec Oil and Gas France and was suspended since his appointment as Chairman and Chief executive officer on March 15th, 2020, shall be terminated. Mr. Édouard Guinotte is therefore entitled to the severance pay under the “Convention collective des cadres et ingénieurs de la métallurgie” (the national collective agreement for executives and engineers in the metallurgy industry), i.e. a gross amount of EUR 439,200, as well as a compensation for notice period equal to 6 months of salary, i.e. a gross amount of EUR 180,000.

4.3 Financial consideration to the non-compete commitment

Given the nature of his duties, it was important, in order to preserve the legitimate interests of the Group, to require Mr. Édouard Guinotte be bound by a non-compete commitment, which he accepted. Such non-compete obligation will cover the following geographical scope: Europe, Middle-East, United States of America, Mexico, Argentina, Brazil, China, Ukraine and Russia.

As consideration for this non-compete commitment, which will apply for 18 months following the termination of his duties as Chairman and Chief executive officer, Mr. Édouard Guinotte will receive a financial consideration equal to EUR 728,857.84 gross, corresponding to 12 months of gross fixed and variable monetary compensation to be paid in 18 monthly installments equal to EUR 40,492.10 gross.

This non-compete commitment and the payment of the associated financial consideration will be subject to the approval of the upcoming Annual General Meeting of the shareholders.

5. Benefits

Mr. Édouard Guinotte will benefit for a period of 12 months from outplacement services, up to EUR 50,000 (excluding VAT).

6. Pension scheme

Mr. Édouard Guinotte will retain his acquired rights under the defined contribution pension scheme known as “Article 82” on the date of termination of his duties as Chairman and Chief executive officer.

The payment of the matching contribution by Vallourec for the 2021 and 2022 financial years, consisting of a part paid to the insurer (50%) and a part paid directly to Mr. Édouard Guinotte (50%), will amount in total to EUR 179,038 gross for 2021 and EUR 39,130 gross for 2022. Such payments will be subject to the approval of the upcoming Annual General Meeting of the shareholders.

6. Otherinformation

Mr. Édouard Guinotte resigned on March 25th, 2022 from his position as member of the Board of Directors, with immediate effect.

In addition, it is reminded that the duties of Mr. Édouard Guinotte as Chairman and Chief executive officer were terminated on March 20th, 2022. As a consequence, and accordingly with the French commercial Code, the duties of Mr. Olivier Mallet as Deputy chief executive officer of the Company expired as of March 20th, 2022 (i.e. upon the appointment of Mr. Philippe Guillemot as new Chairman and Chief executive officer). This expiry was acknowledged by the Board of Directors on March 26th, 2022. From March 21st, 2022 onwards, the provisions of Mr. Olivier Mallet’s employment agreement as Chief financial officer, which were suspended during his appointment as Deputy chief executive officer, are back in force. Mr. Olivier Mallet will carry out his employee duties as Chief financial officer under the same remuneration conditions as those set forth in relation to his duties as Deputy chief executive officer of the Company.

About Vallourec

Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec’s pioneering spirit and cutting edge R&D open new technological frontiers. With close to 17,000 dedicated and passionate employees in more than 20 countries, Vallourec works hand-in-hand with its customers to offer more than just tubes: Vallourec delivers innovative, safe, competitive and smart tubular solutions, to make every project possible.

Listed on Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is part of the CAC Mid 60, SBF 120 and Next 150 indices and is eligible for Deferred Settlement Service.

In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1.

Calendar

May 18th2022

May 24th2022
Release of first quarter 2022 results

Shareholders’ Annual Meeting

For further information, please contact:

Investor relations
Jérôme Friboulet
Tel : +33 (0)1 49 09 39 77
Investor.relations@vallourec.com

Press relations
Héloïse Rothenbühler
Tel: +33 (0)1 41 03 77 50
heloise.rothenbuhler@vallourec.com
Individual shareholders
Toll Free Number (from France): 0 800 505 110
actionnaires@vallourec.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros18.5.2022 15:00:00 CEST | Pressemelding

Lund 18 maj 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) meddelade idag att amerikanska Food and Drug Administration (FDA) har beviljat särläkemedelsstatus för tasquinimod vid behandling av myelofibros. "Särläkemedelsstatus som FDA tilldelat för tasquinimod i myelofibros utgör ett viktigt steg framåt för Active Biotech", säger Helén Tuvesson, VD Active Biotech. "Det öppnar en viktig regulatorisk väg och ger oss potential att snabbt avancera utvecklingen av tasquinimod i denna patientpopulation.” FDAs Orphan Drug Designation program ger särläkemedelsstatus för läkemedelskandidater avsedda för säker och effektiv behandling, diagnos eller förebyggande av ovanliga sjukdomar som drabbar färre än 200.000 människor i USA. Denna särläkemedelsstatus ger 7 års marknadsexklusivitet vid marknadsgodkännande samt vissa andra fördelar. I februari 2022 ingick Active Biotech ett exklusivt licensavtal med Oncode Institute i Nederländerna, som verkar på uppdrag av Erasmus University Medical Center (

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis18.5.2022 15:00:00 CEST | Press release

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of tasquinimod in this patient population.” The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives. In February 2022, Active Biotech entered into an exclusive lice

Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 202218.5.2022 14:00:00 CEST | Pressemelding

2022-05-18 PRESSRELEASE Kommuniké från årsstämma i Arcoma Aktiebolag den 18 maj 2022 Idag, den 18 maj 2022, hölls årsstämma i Arcoma Aktiebolag. Årsstämman genomfördes enbart genom förhandsröstning (poströstning) med stöd av tillfälliga lagregler. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om fastställande av räkenskaper samt resultatdisposition Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat i enlighet med styrelsens förslag i årsredovisningens förvaltningsberättelse, innebärande att ingen vinstutdelning lämnas för 2021 samt att disponibla medel balanseras i ny räkning. Ansvarsfrihet åt styrelseledamöterna och verkställande direktören Årsstämman beslutade att bevilja styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2021. Val och arvodering av styrelse och

Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM18.5.2022 13:11:14 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18 May 2022 Björn Wahlroos will not be available for re-election to Sampo plc’s Board of Directors at the 2023 AGM Björn Wahlroos, Chair of Sampo plc’s Board of Directors, has announced today that he will not be available for re-election to the Board of Directors at the Annual General Meeting to be held in spring 2023. Sampo’s Nomination and Remuneration Committee will communicate on succession in due course. SAMPO PLC For further information, please contact: Sami Taipalus Head of Investor Relations tel. +358 10 516 0030 Distribution: Nasdaq Helsinki London Stock Exchange The principal media Financial Supervisory Authority www.sampo.com

Decisions of Sampo plc’s Annual General Meeting18.5.2022 13:05:00 CEST | Press release

SAMPO PLC DECISIONS OF GENERAL MEETING 18 May 2022 at 2:05 pm Decisions of Sampo plc’s Annual General Meeting The Annual General Meeting of Sampo plc, held today on 18 May 2022, decided to distribute a dividend of EUR 4.10 per share for 2021. The record date for dividend payment is 20 May 2022 and the dividend will be paid on 31 May 2022. The Annual General Meeting adopted the financial accounts for 2021 and discharged the Board of Directors and the CEO from liability for the financial year. The Annual General Meeting increased the number of the members of the Board of Directors to nine members. Christian Clausen, Fiona Clutterbuck, Georg Ehrnrooth, Jannica Fagerholm, Johanna Lamminen, Risto Murto, Markus Rauramo and Björn Wahlroos were re-elected to the Board. Steve Langan was elected as a new member to the Board. The Members of the Board were elected for a term continuing until the close of the next Annual General Meeting. At its organisational meeting, the Board elected Björn Wahlro